Delisting Determination,The Nasdaq Stock Market, LLC,
February 23, 2012, Poniard Pharmaceuticals, Inc. The Nasdaq Stock
Market, Inc. (the Exchange) has determined to remove from
listing the common stock of Poniard Pharmaceuticals, Inc.
(the Company), effective at the opening of the trading
session on March 5, 2012. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rule 5550(a)(2). The Company was notified
of the Staffs determination on July 19, 2011.
The Company appealed the determination to a Hearing Panel.
After a hearing and review of the information
provided by the Company, the Panel issued a decision
granting the Company continued listing pursuant to an exception
through December 31, 2011, by which date the Company was
required to regain compliance with Listing Rule 5550(a)(2).
However, the Company informed the Panel on December 30 that it
could not regain compliance by that date. On December 30, 2011,
the Panel issued a final delisting determination and
notified the Company that trading in the Companys
securities would be suspended on January 3, 2012.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Company became
final on February 13, 2012.